Literature DB >> 19525443

Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance.

Samuel M Cohen1, Richard D Storer, Kay A Criswell, Nancy G Doerrer, Vicki L Dellarco, David G Pegg, Zbigniew W Wojcinski, David E Malarkey, Abigail C Jacobs, James E Klaunig, James A Swenberg, Jon C Cook.   

Abstract

Although rarely occurring in humans, hemangiosarcomas (HS) have become important in evaluating the potential human risk of several chemicals, including industrial, agricultural, and pharmaceutical agents. Spontaneous HS arise frequently in mice, less commonly in rats, and frequently in numerous breeds of dogs. This review explores knowledge gaps and uncertainties related to the mode of action (MOA) for the induction of HS in rodents, and evaluates the potential relevance for human risk. For genotoxic chemicals (vinyl chloride and thorotrast), significant information is available concerning the MOA. In contrast, numerous chemicals produce HS in rodents by nongenotoxic, proliferative mechanisms. An overall framework is presented, including direct and indirect actions on endothelial cells, paracrine effects in local tissues, activation of bone marrow endothelial precursor cells, and tissue hypoxia. Numerous obstacles are identified in investigations into the MOA for mouse HS and the relevance of the mouse tumors to humans, including lack of identifiable precursor lesions, usually late occurrence of the tumors, and complexities of endothelial biology. This review proposes a working MOA for HS induced by nongenotoxic compounds that can guide future research in this area. Importantly, a common MOA appears to exist for the nongenotoxic induction of HS, where there appears to be a convergence of multiple initiating events (e.g., hemolysis, decreased respiration, adipocyte growth) leading to either dysregulated angiogenesis and/or erythropoiesis that results from hypoxia and macrophage activation. These later events lead to the release of angiogenic growth factors and cytokines that stimulate endothelial cell proliferation, which, if sustained, provide the milieu that can lead to HS formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525443     DOI: 10.1093/toxsci/kfp131

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  31 in total

1.  ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Authors:  Stephanie E Busch; Kay E Gurley; Russell D Moser; Christopher J Kemp
Journal:  J Pathol       Date:  2012-05-08       Impact factor: 7.996

Review 2.  Novel therapeutics for Stargardt disease.

Authors:  Louise J Lu; Ji Liu; Ron A Adelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-11       Impact factor: 3.117

3.  A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle.

Authors:  Boglarka Racz; Andras Varadi; Jian Kong; Rando Allikmets; Paul G Pearson; Graham Johnson; Christopher L Cioffi; Konstantin Petrukhin
Journal:  J Biol Chem       Date:  2018-06-05       Impact factor: 5.157

Review 4.  Dog models of naturally occurring cancer.

Authors:  Jennie L Rowell; Donna O McCarthy; Carlos E Alvarez
Journal:  Trends Mol Med       Date:  2011-03-24       Impact factor: 11.951

5.  Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization.

Authors:  Brandi H Gorden; Jong-Hyuk Kim; Aaron L Sarver; Aric M Frantz; Matthew Breen; Kerstin Lindblad-Toh; Timothy D O'Brien; Leslie C Sharkey; Jaime F Modiano; Erin B Dickerson
Journal:  Am J Pathol       Date:  2014-02-11       Impact factor: 4.307

6.  Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma.

Authors:  Beth A Tamburini; Tzu L Phang; Susan P Fosmire; Milcah C Scott; Susan C Trapp; Megan M Duckett; Sally R Robinson; Jill E Slansky; Leslie C Sharkey; Gary R Cutter; John W Wojcieszyn; Donald Bellgrau; Robert M Gemmill; Lawrence E Hunter; Jaime F Modiano
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

7.  A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.

Authors:  Nicoleta Dobri; Qiong Qin; Jian Kong; Kazunori Yamamoto; Zhao Liu; Gennadiy Moiseyev; Jian-Xing Ma; Rando Allikmets; Janet R Sparrow; Konstantin Petrukhin
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

8.  Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling.

Authors:  Shaogang Sun; Song Chen; Fei Liu; Haige Wu; Jonathan McHugh; Ingrid L Bergin; Anita Gupta; Denise Adams; Jun-Lin Guan
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

9.  INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma.

Authors:  Jinming Yang; Sara Kantrow; Jiqing Sai; Oriana E Hawkins; Mark Boothby; Gregory D Ayers; Eric D Young; Elizabeth G Demicco; Alexander J Lazar; Dina Lev; Ann Richmond
Journal:  Cancer Res       Date:  2012-07-26       Impact factor: 12.701

10.  The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma.

Authors:  Daphna Laifenfeld; Annalyn Gilchrist; David Drubin; Milena Jorge; Sean F Eddy; Brian P Frushour; Bill Ladd; Leslie A Obert; Mark M Gosink; Jon C Cook; Kay Criswell; Christopher J Somps; Petra Koza-Taylor; Keith O Elliston; Michael P Lawton
Journal:  Toxicol Sci       Date:  2009-10-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.